Malcolm C. Lloyd-Smith
Keine laufenden Positionen mehr
Vermögen: 6 Mio $ am 31.03.2024
Profil
Malcolm C.
Lloyd-Smith held several positions in the pharmaceutical industry.
He started his career as a Manager of Regulatory Affairs & Quality Assurance at DuPont de Nemours International SARL from 1984 to 1991.
He then worked as the Director of International Regulatory Affairs at DuPont Merck Pharmaceutical Co. from 1991 to 1994.
Malcolm later became the Vice President of Worldwide Regulatory Affairs at DuPont Pharmaceuticals Co. from 1994 to 2002.
He then joined Elan Pharmaceuticals LLC as the Vice President & Head of Global Regulatory Affairs from 2002 to 2008.
Malcolm also served as the Senior VP of Regulatory Affairs, Quality & Clinical at Mallinckrodt Hospital Products, Inc. from 2008 to 2014.
During this time, he also worked as the VP of Regulatory Affairs, Quality & Clinical at Cadence Pharmaceuticals, Inc. from 2012 to 2014.
His most recent position was as the Chief Regulatory Officer at Neurocrine Biosciences, Inc. from 2014 to 2023.
Mr. Lloyd-Smith completed his undergraduate degree at the University of Leeds and his graduate degree at the University of Hertfordshire.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.02.2023 | 42 337 ( 0,04% ) | 6 Mio $ | 31.03.2024 |
Ehemalige bekannte Positionen von Malcolm C. Lloyd-Smith
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | General Counsel | 01.04.2023 |
| CADENCE PHARMACEUTICALS, INC. | General Counsel | 01.09.2014 |
| Cadence Pharmaceuticals , Inc. | General Counsel | 01.09.2014 |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | General Counsel | 01.08.2008 |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | General Counsel | 01.01.2002 |
Ausbildung von Malcolm C. Lloyd-Smith
| University of Leeds | Undergraduate Degree |
| University of Hertfordshire | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Mallinckrodt Hospital Products, Inc.
 Mallinckrodt Hospital Products, Inc. Pharmaceuticals: MajorHealth Technology Mallinckrodt Hospital Products, Inc. operates as a biopharmaceutical company, which develops and commercializes proprietary product candidates used in the hospital setting. The firm offers OFIRMEV (acetaminophen injection), a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The company was founded by Theodore R. Schroeder, David A. Socks, and Cam L. Garner on May 26, 2004 and is headquartered in Hazelwood, MO. | Health Technology |
DuPont de Nemours International SARL
 DuPont de Nemours International SARL Electronic Production EquipmentElectronic Technology DuPont de Nemours International SARL provides automotive, appliance, electronics, filtration and sporting products and services. It also offers a wide range of innovative products and services for markets including agriculture, nutrition, communications, safety and protection, home and construction, transportation and apparel. The company was founded in 1802 and is headquartered in Le Grand-Saconnex, Switzerland. | Electronic Technology |
| Cadence Pharmaceuticals , Inc. |
